Head to Head Contrast: Q32 Bio (NASDAQ:QTTB) & Applied Therapeutics (NASDAQ:APLT)Defense World · Oct 12, 2026
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026PRNewsWire · Sep 30, 2026
Q32 Bio: Durable Hair Regrowth Remains The GoalSeeking Alpha · Sep 26, 2026
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026PRNewsWire · Sep 21, 2026
Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 15, 2026
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D.PRNewsWire · Sep 14, 2026Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.53 | -$0.44 | Beat |
| May 5, 2026 | -$0.68 | -$0.54 | Beat |
| Mar 10, 2026 | -$0.85 | $3.65 | Beat |
| Nov 13, 2025 | -$1.39 | -$0.60 | Beat |
| Aug 6, 2025 | -$1.14 | -$0.78 | Beat |
| May 8, 2025 | -$1.23 | -$0.90 | Beat |